|Bid||17.28 x 900|
|Ask||17.29 x 1000|
|Day's Range||16.96 - 17.59|
|52 Week Range||16.63 - 39.59|
|Beta (3Y Monthly)||2.01|
|PE Ratio (TTM)||37.50|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.56|
Mylan NV NASDAQ/NGS:MYLView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for MYL with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding MYL totaled $2.82 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a long-acting muscarinic antagonist (LAMA), which is the first and only once-daily, nebulized bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target
Insider Monkey finished processing more than 738 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2019. What do these smart investors think about Mylan N.V. (NASDAQ:MYL)? Mylan N.V. (NASDAQ:MYL) was in 30 hedge funds' portfolios at the end of the first quarter of […]
Union pension fund adviser CtW Investment Group on Friday urged Mylan NV shareholders to vote against the company's four director nominees, who are on the board's nominating and governance committee. In a letter to shareholders http://ctwinvestmentgroup.com/wp-content/uploads/2019/06/Mylan_Final_6_7_2019.pdf, CtW said that Mylan needs a clawback that includes recoupment of executive pay for misconduct related to supervisory failures and not just conduct that results in financial restatements.
Union pension fund adviser CtW Investment Group on Friday urged Mylan NV shareholders to vote against the company's nominees for the board's nominating and governance committee. In a letter to shareholders http://ctwinvestmentgroup.com/wp-content/uploads/2019/06/Mylan_Final_6_7_2019.pdf, CtW said that Mylan needs a clawback that includes recoupment of executive pay for misconduct related to supervisory failures and not just conduct that results in financial restatements. CtW works with union pension funds affiliated with Change to Win and estimates that the funds with whom it works hold about 885,000 shares of Mylan.
Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teva Pharmaceutical and Mylan could fork over $2.4 billion in damages, an analyst suggested after pharma company Heritage Pharmaceuticals admitted to fixing the prices of generic drugs.
Investors for Opioid Accountability have already seen success with other pharmaceutical companies in its less than two year effort.
A shareholder proposal at June’s annual meeting of Mylan NV would require the company to seek recoupment of incentives paid to senior executives for serious misconduct and disclose to shareholders what happened even if it doesn't cause the pharmaceutical company to restate its financial reports. The measure to revise Mylan’s clawback policy was put forth by the UAW Retiree Medical Benefits Trust and Investors for Opioid Accountability, although it is not in a binding vote. Mylan said that because the fund doesn't own at least 3 percent of the company's capital, it wasn't possible due to Dutch law to be included in the proxy as a voting item.
Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 28) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Arrowhead ...
FEATURE (CTL) Memorial Day is behind us, and with it the unofficial start of summer. And as we approach the midway point of 2019, it’s a good time to take stock of how stocks are doing. Here’s a look at the five companies with the worst-performing stocks in the S&P 500 this year through last week.
Teva crashed to a 19-year low Tuesday as a lawsuit alleging a generic drugs pricing racket continued to hammer the pharmaceutical company. An analyst cut his price targets on Teva and Mylan.
Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million). In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand. "The divestment is in line with the group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus," Aspen said in a statement.